Minimal Residual Disease Market Trends: Key Innovations Shaping the Future of Cancer Diagnostics
The
minimal residual disease market is drawing growing attention from
diagnostic developers, laboratories and oncology providers seeking earlier,
more precise signals of treatment response. According to Polaris Market
Research, the global MRD testing market was valued at USD 2.38 billion in 2025
and is expected to record a CAGR of 13.1% from 2026 to 2034, with a 2026
estimate of USD 2.69 billion and a projected USD 7.20 billion by 2034. This
article examines the MRD testing technologies behind that trajectory and
what they mean for B2B stakeholders.
What MRD Testing Detects
Minimal residual disease refers to the small number of
cancer cells that remain after treatment, too few for standard tests to detect.
MRD testing is mainly used in blood cancers such as leukemia and lymphoma.
Blood or bone marrow is analyzed with highly sensitive assays, and the results
help doctors understand treatment response, estimate the risk of cancer
returning, and decide on future treatment and monitoring. This is why
healthcare providers are investing more in MRD testing: it shows how far a patient's
cancer cells have responded to treatment and picks up minimal disease that
conventional tests miss. The laboratory result shows whether residual disease
is present and, where possible, quantifies it, after which the physician
interprets the findings to set the care strategy.
MRD Testing Versus Traditional Monitoring
Polaris Market Research's comparison explains why providers
are paying attention. MRD testing can detect one cancer cell in 100,000 to
1,000,000 normal cells, while imaging and standard biomarkers require a tumor
mass of millions of cells. It can flag disease months to years before clinical
relapse, whereas traditional monitoring is reactive. The trade-off is cost,
listed at USD 500 to 3,000+ per assay, against lower costs and established
reimbursement for conventional methods.
Flow Cytometry: The Established Leader
Flow cytometry dominated the minimal residual disease
market by test technique in 2025 with a 34.8% share, owing to its high
sensitivity and broad applicability. Detection rests on identifying
immunophenotypic combinations that appear on leukemic cells but not on healthy
hematopoietic cells. Depending on the setup, flow cytometry can find one
cancer cell among 10,000 to 100,000 healthy bone-marrow cells, with results
available in less than a day. The report notes that numerous investigations
have shown strong correlations between MRD levels measured by flow cytometry
during clinical remission and treatment outcomes. It lists rapid turnaround and
wide availability as advantages, and lower sensitivity versus NGS and a need
for fresh samples as limitations.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞
𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market
Next-Generation Sequencing and PCR
Next-generation sequencing is expected to register a
CAGR of 16.2% during the forecast period, driven by its ability to detect
multiple genetic markers with high sensitivity. Continuing advances in
sequencing are anticipated to shorten turnaround time and improve accuracy,
while the expansion of the personalized medicine biomarkers market is expected
to lift demand. Broader enablers cited include cloud computing and data
integration, genome mapping programs, and a better regulatory and reimbursement
environment for NGS-based diagnostic tests.
Bioinformatics plays an important role in analyzing the
complex data these tests generate, and the report lists higher cost, longer
turnaround and the need for bioinformatics expertise as limitations. AI is
expected to speed analysis, and automation may reduce laboratory workload. PCR
is expected to grow at a 12.6% CAGR, supported by its established use, high
sensitivity and faster turnaround time.
Liquid Biopsy and ctDNA Testing: Opening the Door to
Solid Tumors
Polaris Market Research identifies liquid biopsy as a
significant opportunity. Unlike a tissue biopsy, liquid biopsy relies on
a simple blood test and can help detect cancer cells circulating in the body,
which could promote MRD testing as a regular screening procedure. Researchers
are developing liquid biopsy-based approaches for solid tumors, and
successful commercialization is expected to fuel the market.
ctDNA testing, which detects tumor-related DNA
fragments in blood, supports this expansion by allowing repeated monitoring
from a simple blood sample and potentially reducing invasive procedures. The
solid tumors segment is expected to grow at a 15.4% CAGR, with companies
developing tests for colorectal, lung, breast and other solid tumors.
Regional Snapshot
North America dominated in 2025 with a 45.7% revenue share,
supported by strong patient and physician awareness. Asia Pacific is expected
to grow at a 15.2% CAGR on rising cancer prevalence, and Europe at 12.4%,
driven by advanced healthcare infrastructure and investment in precision
medicine.
Key Players and Competitive Focus
Key players named by Polaris Market Research include Natera,
Adaptive Biotechnologies, Guardant Health, Roche, QIAGEN, Sysmex and
NeoGenomics. The positioning table links Adaptive's clonoSEQ, FDA-cleared in
2018, to NGS-based immunosequencing, Natera's Signatera to tumor-informed NGS
and ctDNA, and Guardant Reveal to liquid biopsy. Companies are focusing
on test accuracy, expansion into solid tumors, and partnerships with hospitals,
pharmaceutical companies and research institutions. Larger companies benefit
from broad laboratory networks, while specialized players compete through
innovative NGS, PCR and personalized MRD platforms.
Conclusion
The outlook for the minimal
residual disease market is positive. Advances in NGS, liquid biopsy
and ctDNA-based technologies are expected to extend use beyond blood cancers
into lung, breast and colorectal cancer. Flow cytometry remains the
leading technique today, while NGS is expected to grow faster. High cost, lack
of standardization and limited reimbursement remain constraints, but increased
standardization and improved reimbursement are likely to propel adoption.
More Trending Latest Reports By Polaris Market Research:
Lithium
Iron Phosphate (LiFePO4) Battery Market
Water
and Wastewater Treatment Equipment Market
Comments
Post a Comment